Analysis of Gut Microbiota Metabolites in Chronic Kidney Disease–Associated Pruritus Using Network Pharmacology and Molecular Docking
نویسندگان
doi
10.30498/ijb.2025.560394.4299چکیده
Background: Chronic kidney disease-associated pruritus (CKD-aP) is a common complication of chronic kidney disease with unclear pathogenesis and limited treatment options. Objectives: This study applied network pharmacology and molecular docking to investigate the interactions between gut microbiota metabolites and biological targets, aiming to identify potential microbiota-derived therapeutic targets for CKD-aP. Methods: The study first extracted gut microbial metabolites from the gutMGene database, and then searched in multiple public databases including DisGeNET, GeneCards and OMIM to find potential targets related to CKD-aP. To identify core targets, we analyzed the protein-protein interaction (PPI) network and conducted functional enrichment studies using the DAVID database, with the methods of gene ontology (GO) classifications and KEGG pathways. Additionally, we mapped out a microbial-substrate-metabolism-target (MSMT) network to better understand their interconnected relationships. Results: 44 common targets were found linking gut microbial metabolites to the disease, with IL6, AKT1, and PPARG emerging as key intervention points for CKD-aP. Our analysis revealed a total of 44 common targets shared between gut microbial metabolites and CKD-aP. Among these, IL6, AKT1, and PPARG were selected as central targets for potential therapeutic intervention. By developing integrated MSMT networks, we discovered that these pivotal targets are influenced by factors such as Lacticaseibacillus paracasei, tryptophan metabolic pathways, and linoleic acid metabolism in alleviating CKD-aP. Further KEGG pathway analysis pinpointed critical signaling, including IL-17 signaling pathway, the C-type lectin receptor signaling pathway and Toll-like receptor signaling pathway as key pathways. Furthermore, molecular docking analysis was performed on active metabolites and core targets, showing that 10-keto-12Z-octadecenoic acid-PPARG, Genipin-CASP3, and Urolithin A-CYP1A1 have good binding activity. Conclusion: Gut microbiota metabolites play a therapeutic role in CKD-aP mainly through microflora (Lacticaseibacillus paracasei), metabolites (tryptophan metabolism, linoleic acid, 10-keto-12Z-octadecenoic acid, Genipin, and Urolithin A), signaling pathways (IL-17 signaling pathway, the C-type lectin receptor signaling pathway and Toll-like receptor signaling pathway), and targets (L6, AKT1, PPARG, EGFR, CASP3, JUN, CXCL8, RELA, CYP1A1). The above findings are hoped to provide scientific basis for researching the potential mechanisms and possible treatment approaches for CKD-aP.